A	B	C	D	E	F	G	H
1	Main
2
3		TAK-242 (resatorvid)	Sepsis	1	TLR4
4		SNT-MC17 (idebenone)	Friedreich's Ataxia	Santhera		III
5		AMG706 (motesanib)	Cancer	AMGN	Kinase	III
6		TAK-379 failure
7		TAK-013	Endometriosis		LHRH antagonist
8		Omontys (fka Hematide, peginesatide)	Anemia	Affymxa	EPO
9		Zafatek (fka SYR-472) (trelagliptin)	Type 2 Diabetes	100% (Furiex acquisition)	DPP4	Approved in Japan
10		Mepact (mifamurtide)	Osteosarcoma	1		EU 09
11		Basen (voglibose)	Type 2 Diabetes	1
12		Edarbi (TAK-491 (azilsartan)) TAK-536?	Hypertension	1	ARB	NDA US	NCE
13		ferumoxytol	Anemia	AMAG; deal terminated		Japan rights only
14		Lotriga (TAK-085)	Hypertriglyceridemia	Pronova	EPA/DHA
15		Galantamine	Alzheimer's	JNJ
16
17		TAK-583	Neuropathic Pain			discontinued in 2008
18		ATL-692 (cetilistat)	Obesity	Norgine	lipase inhibitor	III JP
19		MCC-135 (caldaret)	CHF		Ca++ uptake enhancer
20		TAK-370 (mosapride)	GERD		5-HT4 agonist	approved in some Asian countries?
21		IY-81149			PPI
22		TAK-428	Diabetic neuropathy	1	oral NGF agonist	II US/EU
23		TAK-442 (letaxaban)	Thromboembolism	1	Factor Xa	II US/EU
24		TAK-654 (sipoglitazar)	Type 2 Diabetes		PPAR
25		TAK-700 (orteronel)	HRPC	1	Androgen inhibitor	II
26		MLN0518 (tandutinib)	Glioblastoma	1	FLT3	II
27		Lu AA24530 (tedatioxetine)	Depression	LUN DC		II
28		MLN8237 (alisertib)	NHL	1	Aurora	II
29		CBP501	NSCLC	CanBas	calmodulin	II
30		AMG665 (conatumumab)	Cancer	AMGN	DR5	I
31		AMG386 (trebananib)	Cancer	AMGN	Angiopoietin	I
32		AMG479 (ganitumab)	Cancer	AMGN	IGF-1R	I
33		TAK-100	Type 2 Diabetes	1	DPP4	I
34		TAK-591	Hypertension	1	ARB	I
35		TAK-329	Glucokinase	1		I
36		TAK-875	Type 2 Diabetes	1	GPR40	II
37		TAK-851	HPV	1		II US/EU		Topical
38		TAK-683 (metastin)	HRPC	1	KISS1R agonist	I
39		TAK-448 (metastin)	HRPC	1	KISS1R	I
40		TAK-285	Cancer	1	HER2	I
41		TAK-802	Hypoactive bladder		acetylcholinesterase